NYMC Faculty Publications
Derhamnosylmaysin Inhibits Adipogenesis via Inhibiting Expression of Pparγ and C/Ebpα in 3T3-L1 Cells
Author Type(s)
Faculty
Journal Title
Molecules
Document Type
Article
Publication Date
6-30-2022
Department
Public Health
Abstract
We investigated the effects of derhamnosylmaysin (DM) on adipogenesis and lipid accumulation in 3T3-L1 adipocytes. Our data showed that DM inhibited lipid accumulation and adipocyte differentiation in 3T3-L1 cells. Treatment of 3T3-L1 adipocytes with DM decreased the expression of major transcription factors, such as sterol regulatory element-binding protein-1c (SREBP-1c), the CCAAT-enhancer-binding protein (CEBP) family, and peroxisome proliferator-activated receptor gamma (PPARγ), in the regulation of adipocyte differentiation. Moreover, the expression of their downstream target genes related to adipogenesis and lipogenesis, including adipocyte fatty acid-binding protein (aP2), lipoprotein lipase (LPL), stearyl-CoA-desaturase-1 (SCD-1), acetyl-CoA carboxylase (ACC), and fatty acid synthase (FAS), was also decreased by treatment with DM during adipogenesis. Additionally, DM attenuated insulin-stimulated phosphorylation of Akt. These results first demonstrated that DM inhibited adipogenesis and lipogenesis through downregulation of the key adipogenic transcription factors SREBP-1c, the CEBP family, and PPARγ and inactivation of the major adipogenesis signaling factor Akt, which is intermediated in insulin. These studies demonstrated that DM is a new bioactive compound for antiadipogenic reagents for controlling overweight and obesity.
Recommended Citation
Cho, H., Jang, S., Won, C., Kim, C., Kim, H., Kim, T. H., & Cho, J. (2022). Derhamnosylmaysin Inhibits Adipogenesis via Inhibiting Expression of Pparγ and C/Ebpα in 3T3-L1 Cells. Molecules, 27 (13). https://doi.org/10.3390/molecules27134232
